Get started
Author

Nancy Paz

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
2014 · Ashish V. Kalra, Jaeyeon Kim, et al. · Cancer Research · 199
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
2017 · Huang-Chiao Huang, Imran Rizvi, et al. · Cancer Research · 106
Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
2015 · Min H. Kang, Jing Wang, et al. · Clinical Cancer Research · 103
Mice deficient in PKC theta demonstrate impairedin vivoT cell activation and protection from T cell-mediated inflammatory diseases
2006 · Karen Anderson, Michael Fitzgerald, et al. · Autoimmunity · 69
Synthesis and estrogen receptor binding affinity of a porphyrin-estradiol conjugate for targeted photodynamic therapy of cancer
1999 · David A. James, Narasimha Swamy, et al. · Bioorganic & Medicinal Chemistry Letters · 52
Use of molecular imaging to quantify response to IKK‐2 inhibitor treatment in murine arthritis
2006 · Elena S. Izmailova, Nancy Paz, et al. · Arthritis & Rheumatism · 48
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer
2017 · Shannon C. Leonard, Helen Lee, et al. · Anti-Cancer Drugs · 34
Molecular Modeling, Affinity Labeling, and Site-Directed Mutagenesis Define the Key Points of Interaction between the Ligand-Binding Domain of the Vitamin D Nuclear Receptor and 1α,25-Dihydroxyvitamin D3
2000 · Narasimha Swamy, Wenrong Xu, et al. · Biochemistry · 32
Abstract 2065: Magnetic resonance imaging with an iron oxide nanoparticle demonstrates the preclinical feasibility of predicting intratumoral uptake and activity of MM-398, a nanoliposomal irinotecan (nal-IRI)
2014 · Ashish V. Kalra, Joseph Spernyak, et al. · Cancer Research · 13
Deposition characteristics and resulting DNA damage patterns of liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts.
2018 · Shannon C. Leonard, Nancy Paz, et al. · Journal of Clinical Oncology · 4
P1.07-006 Preclinical Support for Evaluation of Irinotecan Liposome Injection (nal-IRI, MM-398) in Small Cell Lung Cancer
2017 · Shannon Leonard, Helen Lee, et al. · Journal of Thoracic Oncology · 4
PDF
DNA damage with liposomal irinotecan (nal-IRI) in pancreatic cancer xenografts: Multimodal analysis of deposition characteristics.
2018 · Stephan G Klinz, Shannon C. Leonard, et al. · Journal of Clinical Oncology · 3
Abstract C293: Irinotecan sucrosofate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [18F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model.
2013 · Stephan G. Klinz, Jinzi Zheng, et al. · Molecular Cancer Therapeutics · 3
Abstract A6: Sustained intratumoral activation of MM-398 results in superior activity over irinotecan demonstrated by using a systems pharmacology approach
2012 · Jaeyeon Kim, Eliel Bayever, et al. · Cancer Research · 3
Abstract A63: MM-398/PEP02, a novel liposomal formulation of irinotecan, demonstrates stromal-modifying anticancer properties.
2012 · Nancy Paz, Peter Laivins, et al. · Tumor Biology · 2
Abstract C207: Identifying differential mechanisms of action for MM-398/PEP02, a novel nanotherapeutic encapsulation of irinotecan.
2011 · Stephan G. Klinz, Nancy Paz, et al. · Molecular Cancer Therapeutics · 2
Data from Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
2023 · Ashish V. Kalra, Jaeyeon Kim, et al. · 1
Abstract B47: Nanoliposomal irinotecan (nal-IRI) is an active treatment and reduces hypoxia as measured through longitudinal imaging using [18F]FAZA-PET in an orthotopic patient-derived model of pancreatic cancer
2016 · Stephan Klinz, Jinzi Zheng, et al. · Cancer Research · 1
Abstract 4830: Preclinical anti-tumor activity of nanoliposomal irinotecan (Nal-IRI, MM-398) + 5-FU + oxaliplatin in pancreatic cancer
2016 · Daniel F. Gaddy, Helen Lee, et al. · Cancer Research · 1
Abstract 4626: Evaluating the pharmacodynamics and pharmacokinetic effects of MM-398, a nanoliposomal irinotecan (nal-IRI) in subcutaneous xenograft tumor models of human squamous cell carcinoma and small cell lung cancers
2014 · Daniel C. Chan, Ashish Kalra, et al. · Cancer Research · 1
Abstract 5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398.
2013 · Ashish Kalra, Jaeyeon Kim, et al. · Cancer Research · 1
Abstract 5696: Evaluating determinants for enhanced activity of MM-398/PEP02; a novel nanotherapeutic encapsulation of irinotecan (CPT-11)
2012 · Ashish Kalra, Stephan Klinz, et al. · Cancer Research · 1
Figure S2 from Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
2023 · Huang-Chiao Huang, Imran Rizvi, et al.
Data from Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
2023 · Huang-Chiao Huang, Imran Rizvi, et al.
Figure S1 from Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery
2023 · Huang-Chiao Huang, Imran Rizvi, et al.
Works count: 55
Citation count: 683
H-index: 9
I10-index: 9
Year
Topic
Type